全文获取类型
收费全文 | 1441130篇 |
免费 | 121799篇 |
国内免费 | 6610篇 |
专业分类
耳鼻咽喉 | 18155篇 |
儿科学 | 45830篇 |
妇产科学 | 38332篇 |
基础医学 | 197410篇 |
口腔科学 | 38334篇 |
临床医学 | 131574篇 |
内科学 | 299914篇 |
皮肤病学 | 33487篇 |
神经病学 | 120788篇 |
特种医学 | 58906篇 |
外国民族医学 | 277篇 |
外科学 | 224954篇 |
综合类 | 33239篇 |
现状与发展 | 3篇 |
一般理论 | 571篇 |
预防医学 | 116123篇 |
眼科学 | 30703篇 |
药学 | 101150篇 |
7篇 | |
中国医学 | 2384篇 |
肿瘤学 | 77398篇 |
出版年
2018年 | 15329篇 |
2017年 | 12113篇 |
2016年 | 14403篇 |
2015年 | 16321篇 |
2014年 | 22815篇 |
2013年 | 34234篇 |
2012年 | 42792篇 |
2011年 | 45870篇 |
2010年 | 28375篇 |
2009年 | 27697篇 |
2008年 | 43131篇 |
2007年 | 46103篇 |
2006年 | 47080篇 |
2005年 | 45889篇 |
2004年 | 43707篇 |
2003年 | 42738篇 |
2002年 | 40306篇 |
2001年 | 67041篇 |
2000年 | 68664篇 |
1999年 | 57605篇 |
1998年 | 18131篇 |
1997年 | 16162篇 |
1996年 | 16953篇 |
1995年 | 17102篇 |
1994年 | 15819篇 |
1993年 | 14890篇 |
1992年 | 47643篇 |
1991年 | 46280篇 |
1990年 | 44457篇 |
1989年 | 42281篇 |
1988年 | 39195篇 |
1987年 | 38485篇 |
1986年 | 36269篇 |
1985年 | 35127篇 |
1984年 | 27039篇 |
1983年 | 22793篇 |
1982年 | 14787篇 |
1981年 | 13315篇 |
1980年 | 12505篇 |
1979年 | 23927篇 |
1978年 | 17567篇 |
1977年 | 14813篇 |
1976年 | 13565篇 |
1975年 | 14077篇 |
1974年 | 16394篇 |
1973年 | 15639篇 |
1972年 | 14359篇 |
1971年 | 13145篇 |
1970年 | 11993篇 |
1969年 | 11193篇 |
排序方式: 共有10000条查询结果,搜索用时 15 毫秒
81.
Assessment of Myocardial Infarct Size by Three‐Dimensional and Two‐Dimensional Speckle Tracking Echocardiography: A Comparative Study to Single Photon Emission Computed Tomography 下载免费PDF全文
82.
83.
Vestibular function laboratories utilize a multitude of diagnostic instruments to evaluate a dizzy patient. Caloric irrigators, oculomotor stimuli, and rotational chairs produce a stimulus whose accuracy is required for the patient response to be accurate. Careful attention to everything from cleanliness of equipment to threshold adjustments determine on a daily basis if patient data are going to be correct and useful. Instrumentation specifications that change with time such as speed and temperature must periodically be checked using calibrated instruments. 相似文献
84.
85.
Feasibility and Diagnostic Potential of Pulmonary Transit Time Measurement by Contrast Echocardiography: A Pilot Study 下载免费PDF全文
86.
Weiyu Ye Anna Olsson-Brown Robert A. Watson Vincent T. F. Cheung Robert D. Morgan Isar Nassiri Rosalin Cooper Chelsea A. Taylor Umair Akbani Oliver Brain Rubeta N. Matin Nicholas Coupe Mark R. Middleton Mark Coles Joseph J. Sacco Miranda J. Payne Benjamin P. Fairfax 《British journal of cancer》2021,124(10):1661
Background Immune checkpoint blockers (ICBs) activate CD8+ T cells, eliciting both anti-cancer activity and immune-related adverse events (irAEs). The relationship of irAEs with baseline parameters and clinical outcome is unclear.Methods Retrospective evaluation of irAEs on survival was performed across primary (N = 144) and secondary (N = 211) independent cohorts of patients with metastatic melanoma receiving single agent (pembrolizumab/nivolumab—sICB) or combination (nivolumab and ipilimumab—cICB) checkpoint blockade. RNA from pre-treatment and post-treatment CD8+ T cells was sequenced and differential gene expression according to irAE development assessed.Results 58.3% of patients developed early irAEs and this was associated with longer progression-free (PFS) and overall survival (OS) across both cohorts (log-rank test, OS: P < 0.0001). Median survival for patients without irAEs was 16.6 months (95% CI: 10.9–33.4) versus not-reached (P = 2.8 × 10−6). Pre-treatment monocyte and neutrophil counts, but not BMI, were additional predictors of clinical outcome. Differential expression of numerous gene pathway members was observed in CD8+ T cells according to irAE development, and patients not developing irAEs demonstrating upregulated CXCR1 pre- and post-treatment.Conclusions Early irAE development post-ICB is associated with favourable survival in MM. Development of irAEs is coupled to expression of numerous gene pathways, suggesting irAE development in-part reflects baseline immune activation.Subject terms: Immunotherapy, Melanoma 相似文献
87.
88.
89.
Richard Kim Elaine Tan Emily Wang Amit Mahipal Dung-Tsa Chen Biwei Cao Fadzai Masawi Cindy Machado James Yu Dae Won Kim 《The oncologist》2020,25(12):e1893-e1899
Lessons Learned
- The combination of trametinib and sorafenib has an acceptable safety profile, albeit at doses lower than approved for monotherapy.
- Maximum tolerated dose is trametinib 1.5 mg daily and sorafenib 200 mg twice daily.
- The limited anticancer activity observed in this unselected patient population does not support further exploration of trametinib plus sorafenib in patients with hepatocellular carcinoma.
90.
Geneticists have, for years, understood the nature of genome‐wide association studies using common genomic variants. Recently, however, focus has shifted to the analysis of rare variants. This presents potential problems for researchers, as rare variants do not always behave in the same way common variants do, sometimes rendering decades of solid intuition moot. In this paper, we present examples of the differences between common and rare variants. We show why one must be significantly more careful about the origin of rare variants, and how failing to do so can lead to highly inflated type I error. We then explain how to best avoid such concerns with careful understanding and study design. Additionally, we demonstrate that a seemingly low error rate in next‐generation sequencing can dramatically impact the false‐positive rate for rare variants. This is due to the fact that rare variants are, by definition, seen infrequently, making it hard to distinguish between errors and real variants. Compounding this problem is the fact that the proportion of errors is likely to get worse, not better, with increasing sample size. One cannot simply scale their way up in order to solve this problem. Understanding these potential pitfalls is a key step in successfully identifying true associations between rare variants and diseases. 相似文献